BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 9421348)

  • 21. A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression.
    Lépine JP; Goger J; Blashko C; Probst C; Moles MF; Kosolowski J; Scharfetter B; Lane RM
    Int Clin Psychopharmacol; 2000 Sep; 15(5):263-71. PubMed ID: 10993128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
    Sambunaris A; Bose A; Gommoll CP; Chen C; Greenberg WM; Sheehan DV
    J Clin Psychopharmacol; 2014 Feb; 34(1):47-56. PubMed ID: 24172209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression.
    Samuelian JC; Hackett D
    J Psychopharmacol; 1998; 12(3):273-8. PubMed ID: 10958254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
    Leinonen E; Skarstein J; Behnke K; Agren H; Helsdingen JT
    Int Clin Psychopharmacol; 1999 Nov; 14(6):329-37. PubMed ID: 10565799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case-control study.
    Fukuchi T; Kanemoto K
    Int Clin Psychopharmacol; 2002 Mar; 17(2):53-8. PubMed ID: 11890186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Milnacipran and selective serotonin reuptake inhibitors in major depression.
    Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Moclobemide versus clomipramine in the treatment of depression: a double-blind multicentre study in Belgium.
    Dierick M; Cattiez P; Franck G; Burton P; Defleur J; Hermans W; Roelandts A; Wolfrum C; Berger M; Hellstern K
    Acta Psychiatr Scand Suppl; 1990; 360():50-1. PubMed ID: 2248071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder.
    Lopez-Ibor JJ; Conesa A;
    Curr Med Res Opin; 2004 Jun; 20(6):855-60. PubMed ID: 15200743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Tran P; Skolnick P; Czobor P; Huang NY; Bradshaw M; McKinney A; Fava M
    J Psychiatr Res; 2012 Jan; 46(1):64-71. PubMed ID: 21925682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Milnacipran versus other antidepressive agents for depression.
    Nakagawa A; Watanabe N; Omori IM; Barbui C; Cipriani A; McGuire H; Churchill R; Furukawa TA
    Cochrane Database Syst Rev; 2009 Jul; 2009(3):CD006529. PubMed ID: 19588396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders.
    Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
    Psychiatry Clin Neurosci; 2008 Apr; 62(2):197-202. PubMed ID: 18412843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group.
    J Affect Disord; 1990 Apr; 18(4):289-99. PubMed ID: 2140382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial.
    Guelfi JD; Payan C; Fermanian J; Pedarriosse AM; Manfredi R
    Br J Psychiatry; 1992 Apr; 160():519-24. PubMed ID: 1571752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.
    Bakish D; Bose A; Gommoll C; Chen C; Nunez R; Greenberg WM; Liebowitz M; Khan A
    J Psychiatry Neurosci; 2014 Jan; 39(1):40-9. PubMed ID: 24144196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moclobemide versus clomipramine in the treatment of depression: a multicentre trial in Spain.
    Civeira J; Cervera S; Giner J; Allen SR; Hellstern K; Malanowski H; Wirz R; Klar K
    Acta Psychiatr Scand Suppl; 1990; 360():48-9. PubMed ID: 2248070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
    Pancheri P; Scapicchio P; Chiaie RD
    Int J Neuropsychopharmacol; 2002 Dec; 5(4):287-94. PubMed ID: 12466028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical efficacy of milnacipran: placebo-controlled trials.
    Lecrubier Y; Pletan Y; Solles A; Tournoux A; Magne V
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():29-33. PubMed ID: 8923124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.